Enoblituzumab for prostatic neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 4 Oct 2016: Trial registered, NCT02923180
  2. 14 Feb 2017: Trial started, NCT02923180

The trials

NCT02923180: Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

State
Under way
Phase
Phase 2
People
33 taking part
Started
14 Feb 2017
Primary completion
11 Aug 2020
Arms
Enoblituzumab
Results
Posted on the registry
  1. 4 Oct 2016: Trial registered
  2. 14 Feb 2017: Trial started
  3. 24 Aug 2021: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.